Viewing Study NCT05388669


Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2025-12-25 @ 8:27 PM
Study NCT ID: NCT05388669
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-19
First Post: 2022-05-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor: Janssen Research & Development, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module